UniProt O76074
cGMP-specific 3',5'-cyclic phosphodiesterase (O76074)
cGMP-specific 3',5'-cyclic phosphodiesterase (UniProt O76074), EC 3.1.4.35: 88 experimental structures and 1 predicted model on GenesisL1, 15 ligands bound, 43 pockets. Binding sites, druggability and experiment against…
- UniProt
- O76074
- Protein
- cGMP-specific 3',5'-cyclic phosphodiesterase
- EC
- 3.1.4.35
- Experimental structures
- 88
- Predicted models
- 1
- Ligands
- 15
- Pockets
- 43 · 12 records with a druggable one
Structures
89 records of O76074 in the MolNFT archive: 88 experimental, 1 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1RKP | Crystal structure of PDE5A1-IBMX | x-ray diffraction | A | — | — |
| 1RKP | Crystal structure of PDE5A1-ibmx | x-ray diffraction | A | — | — |
| 1T9R | Catalytic Domain Of Human Phosphodiesterase 5A | x-ray diffraction | A | — | — |
| 1T9R | Catalytic domain of human phosphodiesterase 5A | x-ray diffraction | A | — | — |
| 1T9S | Catalytic Domain Of Human Phosphodiesterase 5A in Complex with GMP | x-ray diffraction | A, B | — | — |
| 1T9S | Catalytic domain of human phosphodiesterase 5A in complex with gmp | x-ray diffraction | A, B | — | — |
| 1TBF | Catalytic Domain Of Human Phosphodiesterase 5A in Complex with Sildenafil | x-ray diffraction | A | — | — |
| 1TBF | Catalytic domain of human phosphodiesterase 5A in complex with sildenafil | x-ray diffraction | A | — | — |
| 1UDT | Crystal structure of Human Phosphodiesterase 5 complexed with Sildenafil(Viagra) | x-ray diffraction | A | — | — |
| 1UDT | Crystal structure of human phosphodiesterase 5 complexed with SILDENAFIL(VIAGRA) | x-ray diffraction | A | — | — |
| 1UDU | Crystal structure of Human Phosphodiesterase 5 complexed with tadalafil(Cialis) | x-ray diffraction | A, B | — | — |
| 1UDU | Crystal structure of human phosphodiesterase 5 complexed with TADALAFIL(CIALIS) | x-ray diffraction | A, B | — | — |
| 1UHO | Crystal structure of Human Phosphodiesterase 5 complexed with Vardenafil(Levitra) | x-ray diffraction | A | — | — |
| 1UHO | Crystal structure of human phosphodiesterase 5 complexed with VARDENAFIL(LEVITRA) | x-ray diffraction | A | — | — |
| 1XOZ | Catalytic Domain Of Human Phosphodiesterase 5A In Complex With Tadalafil | x-ray diffraction | A | — | — |
| 1XOZ | Catalytic domain of human phosphodiesterase 5A in complex with tadalafil | x-ray diffraction | A | — | — |
| 1XP0 | Catalytic Domain Of Human Phosphodiesterase 5A In Complex With Vardenafil | x-ray diffraction | A | — | — |
| 1XP0 | Catalytic domain of human phosphodiesterase 5A in complex with vardenafil | x-ray diffraction | A | — | — |
| 2CHM | Crystal structure of N2 substituted pyrazolo pyrimidi s - a flipped binding mode in PDE5 | x-ray diffraction | A | — | — |
| 2CHM | Crystal structure of N2 substituted pyrazolo pyrimidinones - a flipped binding mode in PDE5 | x-ray diffraction | A | — | — |
| 2H40 | Crystal structure of the catalytic domain of unliganded PDE5 | x-ray diffraction | A | — | — |
| 2H40 | Crystal structure of the catalytic domain of unliganded PDE5 | x-ray diffraction | A | — | — |
| 2H42 | Crystal structure of PDE5 in complex with sildenafil | x-ray diffraction | A, B, C | — | — |
| 2H42 | Crystal structure of PDE5 in complex with sildenafil | x-ray diffraction | A, B, C | — | — |
| 2H44 | Crystal structure of PDE5A1 in complex with icarisid II | x-ray diffraction | A | — | — |
| 2H44 | Crystal structure of PDE5A1 in complex with icarisid II | x-ray diffraction | A | — | — |
| 2XSS | Crystal structure of GAFb from the human phosphodiesterase 5 | x-ray diffraction | A, B | — | — |
| 2XSS | Crystal structure of gafb from the human phosphodiesterase 5 | x-ray diffraction | A, B | — | — |
| 3B2R | Crystal Structure of PDE5A1 catalytic domain in complex with Vardenafil | x-ray diffraction | A, B | — | — |
| 3B2R | Crystal structure of PDE5A1 catalytic domain in complex with vardenafil | x-ray diffraction | A, B | — | — |
| 3BJC | Crystal structure of the PDE5A catalytic domain in complex with a novel inhibitor | x-ray diffraction | A | — | — |
| 3BJC | Crystal structure of the PDE5A catalytic domain in complex with a novel inhibitor | x-ray diffraction | A | — | — |
| 3HC8 | Investigation of Aminopyridiopyrazi s as PDE5 Inhibitors: Evaluation of Modifications to the… | x-ray diffraction | A | — | — |
| 3HC8 | Investigation of aminopyridiopyrazinones as PDE5 inhibitors: evaluation of modifications to the… | x-ray diffraction | A | — | — |
| 3HDZ | Identification, Synthesis, and SAR of Amino Substituted Pyrido[3,2b]pryaziones as Potent and… | x-ray diffraction | A | — | — |
| 3HDZ | Identification, synthesis, and sar of amino substituted PYRIDO[3, 2B]PRYAZIONES as potent and… | x-ray diffraction | A | — | — |
| 3JWQ | Crystal structure of chimeric PDE5/PDE6 catalytic domain complexed with sildenafil | x-ray diffraction | A, B, C, D | — | — |
| 3JWQ | Crystal structure of chimeric PDE5/PDE6 catalytic domain complexed with sildenafil | x-ray diffraction | A, B, C, D | — | — |
| 3JWR | Crystal structure of chimeric PDE5/PDE6 catalytic domain complexed with 3-isobutyl-1-methylxanthine… | x-ray diffraction | A, B | — | — |
| 3JWR | Crystal structure of chimeric PDE5/PDE6 catalytic domain complexed with 3-isobutyl-1-methylxanthine… | x-ray diffraction | A, B | — | — |
| 3LFV | crystal structure of unliganded PDE5A GAF domain | x-ray diffraction | A, B | — | — |
| 3LFV | Crystal structure of unliganded PDE5A gaf domain | x-ray diffraction | A, B | — | — |
| 3MF0 | Crystal structure of PDE5A GAF domain (89-518) | x-ray diffraction | A, B | — | — |
| 3MF0 | Crystal structure of PDE5A gaf domain (89-518) | x-ray diffraction | A, B | — | — |
| 3SHY | Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors | x-ray diffraction | A | — | — |
| 3SHY | Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors | x-ray diffraction | A | — | — |
| 3SHZ | Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors | x-ray diffraction | A | — | — |
| 3SHZ | Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors | x-ray diffraction | A | — | — |
| 3SIE | Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors | x-ray diffraction | A, B | — | — |
| 3SIE | Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors | x-ray diffraction | A, B | — | — |
| 3TGE | A novel series of potent and selective PDE5 inhibitor1 | x-ray diffraction | A | — | — |
| 3TGE | A novel series of potent and selective PDE5 INHIBITOR1 | x-ray diffraction | A | — | — |
| 3TGG | A novel series of potent and selective PDE5 inhibitor2 | x-ray diffraction | A | — | — |
| 3TGG | A novel series of potent and selective PDE5 INHIBITOR2 | x-ray diffraction | A | — | — |
| 4G2W | Crystal structure of PDE5A in complex with its inhibitor | x-ray diffraction | A | — | — |
| 4G2W | Crystal structure of PDE5A in complex with its inhibitor | x-ray diffraction | A | — | — |
| 4G2Y | Crystal structure of PDE5A complexed with its inhibitor | x-ray diffraction | A | — | — |
| 4G2Y | Crystal structure of PDE5A complexed with its inhibitor | x-ray diffraction | A | — | — |
| 4I9Z | Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors | x-ray diffraction | A | — | — |
| 4I9Z | Crystal structure of the PDE5A1 catalytic domain in complex with novel inhibitors | x-ray diffraction | A | — | — |
29 records more on the page itself.
Ligands
- ZN · Zinc ion · in 17 records
- MG · Magnesium ion · in 16 records
- SO4 · Sulfate ion · in 8 records
- 2OI · 2-[(4-chlorophenyl)methyl]-5-methoxy-3,10-diazatricyclo[6.4.1.0^{4,13}]trideca-1,4(13),5,7-tetraen-9-one · in 2 records
- 2VI · 5-[bis(fluoranyl)methoxy]-2-[(4-chlorophenyl)methyl]-10-(3-methoxypropyl)-3,10-diazatricyclo[6.4.1.0^{4, 13}]trideca-1,4(13),5,7-tetraen-9-one · in 2 records
- 9M0 · 3-[(2H-1,3-benzodioxol-5-yl)methyl]-8-fluoro-1-(1,3-thiazol-2-yl)[1]benzopyrano[2,3-c]pyrrol-9(2H)-one · in 2 records
- 9T9 · 3-[(2H-1,3-benzodioxol-5-yl)methyl]-8-fluoro-6-{[2-(4-methylpiperazin-1-yl)ethyl]amino}-1-(1,3-thiazol-2-yl)[1]benzopyrano[2,3-c]pyrrol-9(2H)-one · in 2 records
- E6L · 4-[(3-chloranyl-4-methoxy-phenyl)methylamino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimid ine-5-carboxamide · in 2 records
- FZA · (13bS)-4,9-dimethoxy-14-methyl-8,13,13b,14-tetrahydroindolo[2',3':3,4]pyrido[2,1-b]quinazolin-5(7H)-one · in 2 records
- 6LK · 1-(5-chloro-6-methoxypyridin-3-yl)-3-methyl-N-(methylsulfonyl)-1H-indazole-5-carboxamide · in 1 record
- AJR · 2,2'-{[6-{[(4-methoxyphenyl)methyl]amino}-9-(propan-2-yl)-9H-purin-2-yl]azanediyl}di(ethan-1-ol) · in 1 record
- B0C · N-[3-(4,5-diethyl-6-oxo-1,6-dihydropyrimidin-2-yl)-4-propoxyphenyl]-2-(4-methylpiperazin-1-yl)acetamide · in 1 record
- VZF · 2-[bis(2-hydroxyethyl)amino]-6-[(4-methoxyphenyl)methylamino]-9-propan-2-yl-7~{H}-purin-8-one · in 1 record
- WD3 · 3-[2-[[5-chloranyl-2-[(3-fluorophenyl)methylamino]phenyl]methyl]-4-oxidanylidene-3~{H}-quinazolin-7-yl]prop-2-enoic acid · in 1 record
- WDB · (~{E})-3-[2-[(3-chlorophenyl)methyl]-4-oxidanylidene-3~{H}-quinazolin-7-yl]prop-2-enoic acid · in 1 record
Experiment against prediction
- 6L6E chain A against the predicted model O76074: TM-score 0.99, RMSD 0.55 Å
- 3JWQ chain D against the predicted model O76074: TM-score 0.99, RMSD 0.60 Å
- 3JWQ chain D against the predicted model O76074: TM-score 0.99, RMSD 0.60 Å
- 3TGE chain A against the predicted model O76074: TM-score 0.99, RMSD 0.53 Å
- 3TGE chain A against the predicted model O76074: TM-score 0.99, RMSD 0.53 Å
- 3JWR chain A against the predicted model O76074: TM-score 0.99, RMSD 0.65 Å
- 3JWR chain A against the predicted model O76074: TM-score 0.99, RMSD 0.65 Å
- 3HC8 chain A against the predicted model O76074: TM-score 0.99, RMSD 0.53 Å
- 3HC8 chain A against the predicted model O76074: TM-score 0.99, RMSD 0.53 Å
- 3TGG chain A against the predicted model O76074: TM-score 0.99, RMSD 0.54 Å
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.